What is the revenue and EPS growth rate for Rigel Pharmaceuticals year over year?

What is Rigel Pharmaceuticals's gross profit margin?

What is Rigel Pharmaceuticals's latest dividend and current dividend yield?

What does Rigel Pharmaceuticals do and what are its main business segments?

Did Rigel Pharmaceuticals beat or miss consensus estimates last quarter?

What were the key takeaways from Rigel Pharmaceuticals’s earnings call?

What is the market's earnings forecast for Rigel Pharmaceuticals next quarter?

What guidance did Rigel Pharmaceuticals's management provide for the next earnings period?

- **Revenue Surge**: Q3 2025 net product sales of $64.1 million (+65% YoY), driving total revenue to $69.5 million. Updated 2025 guidance: $285-$290 million, up 55%-59% YoY.
- **Pipeline Momentum**: R289 phase 1b dose expansion underway; olutasidenib advancing into glioma and first-line AML/MDS via strategic trials.
- **Financial Strength**: $27.9 million net income, $137.1 million cash, and cost control supporting growth.
- **Strategic Expansion**: Global partnerships (e.g., Kissei, Dr. Reddy’s) and collaborations (MD Anderson, Connect) fueling pipeline and commercial reach.

**【CEO Summary Section】**
- **Revenue Growth**: Total revenue of $69.5 million, with net product sales at $64.1 million, a 65% year-over-year increase. TAVALISSE, GAVRETO, and REZLIDHIA contributed $44.7 million, $11.1 million, and $8.3 million respectively.
- **Pipeline Progress**: R289 phase 1b study in lower-risk MDS nearing dose expansion phase; olutasidenib expanding into glioma and first-line AML/MDS via collaborations with MD Anderson, Connect, and MyloMATCH.
- **Updated Guidance**: 2025 revenue raised to $285-$290 million, with net product sales expected at $225-$230 million, reflecting 55%-59% YoY growth.

**【CFO Financial Commentary】**
- **Financial Health**: Net income of $27.9 million, cash balance of $137.1 million, and cost control leading to $41 million in total costs (down from $41.3 million YoY).
- **Revenue Breakdown**: Contract revenues of $5.4 million from collaborations, including $3.1 million from Grifols and $1.8 million from Kissei.
- **Cost Efficiency**: Favorable gross-to-net dynamics and improved patient access driving commercial performance.

**【Q&A Highlights】**
- **R289 Strategy**: Dose expansion phase comparing 500mg BID and 1000mg QD; potential registrational study design to be determined post-FDA discussions.
- **Glioma Collaboration**: Connect study evaluating olutasidenib as maintenance therapy in high-grade glioma, targeting underserved adolescent and young adult patients.
- **Competitive Positioning**: R289's dual IRAK1/4 inhibition offers unique anti-inflammatory mechanism, differentiating it from HMAs and ESAs in lower-risk MDS.

Rigel Pharmaceuticals, Inc. (RIGL) Q3 2025 Earnings Call Transcript

Product Sales, Net

Contract From Collaborations

Government Contract

RIGL

RIGL fundamentals

You can ask Aime